Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged weight-loss.
Discover the latest retatrutide weight loss results from the Phase 3 TRIUMPH-1 trial. Learn how this triple agonist peptide achieves bariatric-level results.
The Lancet just published the Phase IIb results for elecoglipron, AstraZeneca's once-daily oral GLP-1 receptor agonist. Alex Keane analyzes the VISTA and SOLSTICE clinical data, the science of oral small molecules, and what this means for the future of obesity and diabetes care.
From muscle growth to weight loss, peptides offer promise and peril. Learn to distinguish between unregulated hype and FDA-approved science to make informed health decisions.
No articles match that search.